News & Updates
Christopher Kata and the TrialStat team are exhibiting at this years DPHARM meeting on September 17th through the 18th in booth #21. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #21 at your convenience! We’re looking forward to providing live, personalized…
Read More
Excerpt from the Press Release: TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of a…
Read More
Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish results today from the COSMOS study confirming the high sensitivity and specificity of the Guardant Reveal blood test in predicting recurrence…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of…
Read More
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Excerpt from the Press Release: Carlsbad, CA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI)…
Read More
– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – Excerpt from the Press Release: SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc.…
Read More
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T cell engaging assets to treat solid tumors Excerpt from the Press Release: PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
Read More
We are delighted to announce the opening of our new office location in Yardley, PA. This expansion represents a significant milestone for TrialStat as we continue to grow and strengthen our presence in the Pennsylvania area. Our new office is strategically located at 790 Township Line Rd #175, Yardley, PA, designed to better serve the…
Read More
Excerpt from the Press Release: LOWELL, Mass., July 31, 2024 /PRNewswire/ — Alcyone Therapeutics Inc. (Alcyone), a clinical-stage biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced today that the U.S. Food and Drug Administration (FDA) has provided approval to continue enrollment of the PIERRE study (https://clinicaltrials.gov/ct2/show/NCT05866419) to…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?